The global cephalosporin market size reached US$ 18.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.3 Billion by 2028, exhibiting a growth rate (CAGR) of 2.83% during 2023-2028.
Cephalosporins are beta-lactam antibiotics that function in the way similar to penicillin. These broad-spectrum drugs help in treating numerous bacterial infections such as pneumonia, kidney infections, bone infections, meningitis and various sexually transmitted diseases (STDs). There are currently five generations of cephalosporin drugs available in the market with a slight difference in their antibacterial spectrum. These medicines are also differentiated on the basis their administration, excretion, absorption and the duration of the effect of cephalosporin on the body. There are two ways to administer cephalosporin drugs, namely, oral and intravenous (IV). A course of oral cephalosporins is generally used for curing minor infections that are easy to treat such as strep throat. Whereas, IVs are utilized for more severe infections, like meningitis, as these medicines reach tissues quickly than those administered orally.
At present, the rapidly increasing water and air pollution are the primary reasons for the prevalence of infectious diseases across the globe. This has provided a boost to the demand for cephalosporin drugs worldwide. Other than this, various organizations around the world are taking initiatives to improve the development and delivery of antibiotic treatments. One such program is the Global Antibiotic Research and Development Partnership (GARDP), which is a not-for-profit R&D organization formed by the Drugs for Neglected Disease initiative (DNDi) and World Health Organization (WHO). It focusses on the promotion of public-private partnerships for increasing R&D of new antimicrobial diagnostics and agents. The formation of these partnerships is expected to play a significant role in the growth of the cephalosporin market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cephalosporin market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on generation, route of administration and application.
Breakup by Generation:
First Generation
Second Generation
Third Generation
Fourth Generation
Fifth Generation
Breakup by Route of Administration:
Injection
Oral
Breakup by Application:
Respiratory Tract
Skin Infection
Ear Infection
Urinary Tract Infection
Sexually Transmitted Infection
Others
Breakup by Region:
Asia Pacific
Europe
North America
Middle East and Africa
Latin America
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Limited, Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Abbott, Sun Pharmaceutical Industries Limited, etc.
Report Coverage:
Report Features
Details
Base Year of the Analysis
2022
Historical Period
2017-2022
Forecast Period
2023-2028
Units
US$ Billion
Segment Coverage
Generation, Route of Administration, Application, Region
Region Covered
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Companies Covered
Allergan Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Limited, Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Abbott and Sun Pharmaceutical Industries Limited
Customization Scope
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
10-12 Weeks
Delivery Format
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global cephalosporin market was valued at US$ 18.7 Billion in 2022.
We expect the global cephalosporin market to exhibit a CAGR of 2.83% during 2023-2028.
The high prevalence of numerous bacterial infections, such as pneumonia, kidney infections, bone
infections, meningitis, etc., is primarily driving the global cephalosporin market.
The sudden outbreak of the COVID-19 pandemic has led to extensive R&D activities for the introduction
of combination drugs, including cephalosporin, as an immediate option for effective treatment of the
coronavirus infected patients.
Based on the generation, the global cephalosporin market has been segmented into first generation,
second generation, third generation, fourth generation, and fifth generation. Among these, third
generation cephalosporin holds the majority of the total market share.
Based on the route of administration, the global cephalosporin market can be divided into injection and
oral. Currently, injection represents the largest market share.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin
America, and Middle East and Africa, where Asia Pacific currently dominates the global market.
Some of the major players in the global cephalosporin market include Allergan Plc., Bristol-Myers Squibb
Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Limited, Merck & Co. Inc., Novartis
International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Abbott, Sun
Pharmaceutical Industries Limited, etc.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.